4Buell JF,Gross TG,Woodle ES.Malignancy after transplantation[J].Transplantation,2005,80(2 Suppl):272-274.
5Park JH,Bok HJ,Kim BS,et al.Posttransplant malignant during 30 year at a single center[J].Transplan proc,2000,32(7):1979-1979.
6Sehgal SN.Rapamune (RAPA,Rapamycin,Sirolimus):Mechanism of action immunosuppressive effect result from blockade of signal transduction and inhibition of cell cycle progression[J].Clin Biochem,1998,31(5):335-340.
7Camardo J.The Rapamune era of immunosuppression 2003:the journey from the laboratory to clinical transplantation[J].Transplant Proc,2003,35(Suppl 3A):18-24.
8Ishikawa N,Tanabe K,Tokumoto T,et,al.Clinical study of malignancies after renal transplantation and impact of routine screening for early detection:a single-center experience[J].Transplant proc,2000,32(7):1907-1910.
10Howard RJ,Patton PR,Reed AI et al.The changing causes of graft loss and death after kidney transplantation[J].Transplantation,2002,73(12):1923-1928.
二级参考文献10
1Ondrus D, Pribylineova V, Breza J, et al. The incidence of tumors in renal transplant recipients with long-term immunosuppressive therapy. Int Urology Nephrology, 1999, 31:417-422.
2Hoshida Y, Tsukuma H, Yasunaga Y, et al. Cancer risk after renal transplantation in Japan. Int J Cancer, 1997, 71:517-520.
3Ecder ST, Sever MS, Yildiz A, et al. Kaposi's sarcoma after renal transplantation in Turkey. Clin Transplant, 1998, 12:472-475.
4Danpanich E, Kasiske BL. Risk factors for cancer in renal transplant recipients. Transplantation, 1999, 68:1859-1864.
5Jacques D, Maryvonne H, Diego C, et al. Effect of long-term immunosuppressive in kidney-graft recipient on cancer incidence: randomized comparison of two cyclosporine regimens. Lancet, 1998,351 : 623-628.
